产品详细信息

Description: The HIB19 monoclonal antibody reacts with human CD19, a 95 kDa transmembrane glycoprotein. CD19 is expressed by B cells during all stages of development excluding the terminally differentiated plasma cells. Follicular dendritic cells also express CD19. Together CD21, CD81, Leu13, MHC class II, and CD19 form a multimolecular complex that associates with BCR. Signaling through CD19 induces tyrosine phosphorylation, calcium flux and proliferation of B cells. The SJ25C1 antibody and the HIB19 monoclonal antibody recognize overlapping epitopes.

Applications Reported: This HIB19 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This HIB19 antibody has been pre-diluted and tested by flow cytometric analysis of normal human peripheral blood cells. This may be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Brilliant Violet™ 480 (BV480) is a dye that emits at 479 nm and is intended for use on cytometers equipped with a violet (405 nm) laser. Please make sure that your instrument is capable of detecting this fluorochrome.

When using two or more Super Bright, Brilliant Violet™, Brilliant Ultra Violet™, or other polymer dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Complete Staining Buffer (Product # SB-4401-42) or Brilliant Stain Buffer™ (Product # 00-4409-75) to minimize any non-specific polymer interactions. Please refer to the datasheet for Super Bright Staining Buffer or Brilliant Stain Buffer for more information.

Our internal testing suggests that Brilliant Violet™ 480 (BV480) is not compatible with methanol-based fixation.

Excitation: 440 nm; Emission: 479 nm; Laser: Violet Laser.

BRILLIANT VIOLET™ is a trademark or registered trademark of Becton, Dickinson and Company or its affiliates, and is used under license. Powered by Sirigen™.

靶标信息

CD19 is a member of the immunoglobulin superfamily, characterized by two Ig-like domains, and is expressed on B cells throughout all stages of development, excluding terminally differentiated plasma cells. It is also expressed on follicular dendritic cells and has been observed on myeloid leukemia cells, particularly those of monocytic lineage. CD19 is considered the earliest and broadest B cell-restricted antigen, and its expression is found in all B cell precursor leukemias. CD19 forms a multimolecular complex with CD21, CD81, Leu13, MHC class II, and the B cell receptor (BCR), playing a crucial role in B cell signaling. As a signal-amplifying coreceptor for the BCR, CD19 lowers the threshold for antigen receptor-dependent stimulation, allowing B cells to respond specifically and sensitively to various antigens through low-affinity antigen receptors. Signaling through CD19 induces tyrosine phosphorylation, calcium flux, and proliferation of B cells. Beyond its role as a BCR coreceptor, CD19 can also signal independently of BCR co-ligation, serving as a central regulatory component upon which multiple signaling pathways converge. This makes CD19 an important functional regulator of both normal and malignant B cell proliferation. Mutations in the CD19 gene can result in hypogammaglobulinemia, a condition characterized by low levels of immunoglobulins, while CD19 overexpression can lead to B cell hyperactivity. CD19 is expressed on 100% of peripheral B cells, as defined by the expression of kappa or lambda light chains, underscoring its significance in B cell function and immune regulation.